ArticleFrontiers in microbiology2026
SIRT3 deficiency aggravates renal injury and fibrosis in chronic kidney disease and is associated with intestinal barrier dysfunction and gut microbiota dysbiosis.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) is a progressive disorder characterized by persistent renal dysfunction, inflammation, and fibrosis. Sirtuin 3 (SIRT3), a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase, has been implicated in the regulation of mitochondrial homeostasis, oxidative stress, and renal injury. However, whether SIRT3 participates in CKD progression through gut-kidney axis-related alterations remains unclear. This study investigated the role of SIRT3 in renal injury, fibrosis, intestinal barrier dysfunction, and gut microbiota dysbiosis in CKD. Methods: An adenine-induced CKD model was established in global SIRT3 knockout mice. Renal function, inflammatory markers, histopathological injury, fibrosis-related proteins, colonic injury, intestinal barrier-related proteins, and gut microbial composition were evaluated. In parallel, human proximal tubular epithelial HK-2 cells were treated with transforming growth factor-β1 (TGF-β1), with or without the SIRT3 inhibitor 3-TYP, to assess profibrotic responses and apoptosis Results: SIRT3 deficiency alone did not produce overt abnormalities under basal conditions, but significantly aggravated adenine-induced renal dysfunction, inflammatory responses, tubulointerstitial fibrosis, and structural kidney injury. In CKD mice, SIRT3 deficiency also worsened colonic injury, reduced the expression of zonula occludens-1 and occludin, and was associated with more pronounced gut microbiota dysbiosis. Discussion: These findings indicate that SIRT3 exerts a protective role in CKD progression. Loss of SIRT3 aggravates CKD progression not only by worsening local renal injury, but also in association with gut-kidney axis-related abnormalities. Collectively, our results suggest that SIRT3 may represent a potential therapeutic target for CKD and provide a basis for further mechanistic investigation of its role in renal fibrosis and gut-kidney axis dysfunction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.